Insider Selling: Mirati Therapeutics Inc (NASDAQ:MRTX) Director Sells 3,000 Shares of Stock

Mirati Therapeutics Inc (NASDAQ:MRTX) Director Bruce L. A. Carter sold 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $94.74, for a total transaction of $284,220.00. Following the transaction, the director now directly owns 3,000 shares of the company’s stock, valued at approximately $284,220. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Mirati Therapeutics stock traded down $2.00 during trading hours on Friday, hitting $87.03. The company’s stock had a trading volume of 1,072,190 shares, compared to its average volume of 679,952. Mirati Therapeutics Inc has a 1-year low of $34.39 and a 1-year high of $111.99. The business has a fifty day moving average of $86.58 and a 200 day moving average of $89.33. The company has a market capitalization of $3.78 billion, a PE ratio of -27.28 and a beta of 2.05.

Mirati Therapeutics (NASDAQ:MRTX) last released its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.25) by ($0.13). Mirati Therapeutics had a negative return on equity of 48.60% and a negative net margin of 2,698.66%. The business had revenue of $0.99 million during the quarter, compared to analyst estimates of $0.50 million. Analysts anticipate that Mirati Therapeutics Inc will post -5.36 EPS for the current year.

Several equities analysts recently commented on MRTX shares. BidaskClub lowered shares of Mirati Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday. Citigroup set a $130.00 price target on shares of Mirati Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Cantor Fitzgerald upped their price target on shares of Mirati Therapeutics from $81.00 to $85.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 29th. Zacks Investment Research raised shares of Mirati Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday. Finally, B. Riley dropped their price target on shares of Mirati Therapeutics from $92.00 to $83.00 and set a “neutral” rating for the company in a research report on Wednesday, September 11th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and thirteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $105.67.

Institutional investors have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Mirati Therapeutics by 19.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,422 shares of the biotechnology company’s stock valued at $146,000 after purchasing an additional 235 shares in the last quarter. Mackay Shields LLC grew its holdings in Mirati Therapeutics by 1.6% during the 3rd quarter. Mackay Shields LLC now owns 19,200 shares of the biotechnology company’s stock valued at $1,496,000 after purchasing an additional 300 shares in the last quarter. First Mercantile Trust Co. grew its holdings in Mirati Therapeutics by 34.7% during the 3rd quarter. First Mercantile Trust Co. now owns 1,169 shares of the biotechnology company’s stock valued at $91,000 after purchasing an additional 301 shares in the last quarter. Aperio Group LLC acquired a new stake in Mirati Therapeutics during the 2nd quarter valued at $50,000. Finally, NumerixS Investment Technologies Inc acquired a new stake in Mirati Therapeutics during the 2nd quarter valued at $52,000.

Mirati Therapeutics Company Profile

Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers.

Recommended Story: Book Value Of Equity Per Share – BVPS Explained

Insider Buying and Selling by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.